Studies suggest that SMAD1, a downstream effector in the TGF-β pathway, may interact with MEK/ERK signaling to fine-tune cell proliferation in specific cancer contexts, adding an additional layer of complexity to the regulation of tumor growth [65]. This evidence concerns the gene MAP2K7 and cancer.